Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. provided earnings guidance for the nine months ended September 30, 2016. The board of directors of the company informed the shareholders of the company and potential investors that, based on the preliminary assessment of the unaudited consolidated management accounts of the Group, the Group is expected to record a significant increase in the profit attributable to the owners of the Company for the nine months ended 30 September 2016, as compared to the corresponding period in 2015. The increase was mainly due to the fact that the Group disposed of Taizhou Neptunus Nano Bio-medical Technology Company Limited at the end of 2015 and Jiangsu Neptunus Bio-pharmaceutical Company Limited in January 2016, both of which are research and development-focused companies, as a result of the disposals, the Group's corresponding research and development expenses that would have been incurred by these two subsidiaries decreased by approximately RMB 9 million for the Relevant Comparison Period; and the Group repaid partial external borrowings during the Relevant Comparison Period, as a result of the repayment, the Group's finance costs for the Relevant Comparison Period had decreased by nearly RMB 5 million, as compared to the corresponding period in 2015.